Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
293
datasets available to search
ShareScore release 0.9.0
Dataset results
293 results for “PARP”
ADP-ribosylation of STAT1α by PARP-1 is Required for IFNγ-stimulated Transcriptional Responses in Macrophages [H3K27ac_ChIP-Seq_BMDM]
GEO Series GSE147952. Mus musculus. 16 samples. Type: Genome binding/occupancy profiling by high throughput sequencing.
A quantitative chemotherapy genetic interaction map identifies new factors associated with PARP inhibitor resistance
GEO Series GSE101904. Homo sapiens. 8 samples. Type: Expression profiling by high throughput sequencing.
STING Agonism Reprograms Tumor-associated Macrophages and Overcomes Resistance to PARP inhibition in BRCA1-deficient Models of Breast Cancer
GEO Series GSE201017. Mus musculus. 14 samples. Type: Expression profiling by high throughput sequencing.
Lack of synergy between AR targeted therapies and PARP inhibition in homologous recombination- proficient prostate cancer
GEO Series GSE315878. Homo sapiens. 70 samples. Type: Expression profiling by high throughput sequencing.
Genome-wide maps of PARP-1-bound nucleosomes (human)
GEO Series GSE61916. Homo sapiens. 2 samples. Type: Genome binding/occupancy profiling by high throughput sequencing.
SPARCLE, a p53-induced lncRNA, controls apoptosis after genotoxic stress by promoting PARP-1 cleavage
GEO Series GSE144510. Homo sapiens. 12 samples. Type: Expression profiling by high throughput sequencing.
A novel CRISPR-engineered prostate cancer cell line defines the AR-V transcriptome and identifies PARP inhibitor sensitivities.
GEO Series GSE126306. Homo sapiens. 6 samples. Type: Expression profiling by high throughput sequencing.
PARP Inhibitor BMN-673 and Temozolomide or Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic Solid Tumors
ClinicalTrials.gov study NCT02049593. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Study of CYH33 in Combination With Olaparib an Oral PARP Inhibitor in Patients With Advanced Solid Tumors.
ClinicalTrials.gov study NCT04586335. IPD Sharing: NO. Countries: 3. Publications: 0.
Study to Evaluate TNG348 Alone and With a PARP Inhibitor in Patients With BRCA 1/2 Mutant or HRD+ Solid Tumors
ClinicalTrials.gov study NCT06065059. IPD Sharing: NO. Countries: 1. Publications: 0.
A Study of AK112 Combined With PARP Inhibitor in the Treatment of Recurrent Ovarian Cancer
ClinicalTrials.gov study NCT04999605. IPD Sharing: NO. Countries: 1. Publications: 0.
Real World Data Analysis of PARP Inhibitors Use in Patients With Ovarian Cancer
ClinicalTrials.gov study NCT04724031. IPD Sharing: Not stated. Countries: 1. Publications: 0.
PARP Inhibition, Stereotactic Body Radiotherapy and Immunotherapy for Metastatic or Advanced Sarcoma (PRIMA)
ClinicalTrials.gov study NCT06074692. IPD Sharing: UNDECIDED. Countries: 1. Publications: 0.
Metabolite Levels in Ovarian Cancer Patients Receiving Maintenance PARP Inhibitors
ClinicalTrials.gov study NCT04917744. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Trastzumab Deruxtecan Versus SOC in Recurrent Ovarian That Progressed on Prior PARP Inhibitor Therapy
ClinicalTrials.gov study NCT07340164. IPD Sharing: NO. Countries: 1. Publications: 0.
[18F]FTT Positron Emission Tomography for the Measurement of PARP Tumor Expression in Patients With Metastatic Breast Cancer
ClinicalTrials.gov study NCT06502691. IPD Sharing: NO. Countries: 1. Publications: 0.
Effects of Cytotoxic Chemotherapy and PARP Inhibition on the Genomic Contexture of Ovarian Cancer
ClinicalTrials.gov study NCT04752865. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Genetic Landscape in Women with Metastatic Ovarian Cancer Before and During Treatment with PARP Inhibitors
ClinicalTrials.gov study NCT06785077. IPD Sharing: NO. Countries: 1. Publications: 0.
A Study to Assess the Safety and Pharmacokinetics of an Inhibitor of PARP in Combination With Dacarbazine
ClinicalTrials.gov study NCT00516802. IPD Sharing: Not stated. Countries: 2. Publications: 0.
Circulating Tumor DNA (ctDNA) Monitoring in the Assessment and Prediction of the Efficacy of PARP Inhibitors (PARPi)
ClinicalTrials.gov study NCT05116579. IPD Sharing: Not stated. Countries: 1. Publications: 0.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.